Bio-Techne Reports Q4 2025 Earnings and Fiscal Year Performance
Bio-Techne reported 3% organic revenue growth in Q4 2025 and 5% for the fiscal year. The company highlighted strong performance in its GMP Reagents segment, which grew 20% in Q4, and the Biopharma end market, which delivered high single-digit growth. Protein Sciences showed 4% organic growth in Q4, while Diagnostics and Spatial Biology declined 1% in the quarter.
Tickers: $TECH
Topics: acquisitions geographic_results revenue_growth segment_performance